Universiy of Texas Southwestern Medical Center
Welcome,         Profile    Billing    Logout  
 13 Trials 
36 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Kumthekar, Priya
NCT02847559: Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma

Recruiting
2
27
US
Bevacizumab, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF rhuMAb, Avastin, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, Electric Field Therapy, NovoTTF-200A Device, NovoTTF-200A, NovoTTF-200A System, NovoTTFields, NovoTumor Treatment Fields, Optune, Optune Device, Quality-of-Life Assessment, Quality of Life Assessment
Northwestern University, NovoCure Ltd., National Cancer Institute (NCI)
Anaplastic (Malignant) Meningioma, Atypical Meningioma, Grade II Meningioma, Grade III Meningioma, Recurrent Meningioma, Supratentorial Meningioma
09/26
12/26
NCT04145115: A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden

Suspended
2
37
US
Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS 734016, BMS-734016, BMS734016, Ipilimumab Biosimilar CS1002, MDX 010, MDX-010, MDX-CTLA4, MDX010, Yervoy, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo
National Cancer Institute (NCI)
Astrocytoma, IDH-Mutant, Grade 4, Diffuse Glioma, Glioblastoma, IDH-Wildtype, Secondary Glioblastoma
05/25
05/25
PROTECT, NCT04469075: Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields

Recruiting
2
58
US
Clindamycin Phosphate, Triamcinolone Acetonide
Memorial Sloan Kettering Cancer Center
Glioblastoma, Recurrent Glioblastoma, Skin Toxicity
07/25
07/25
A071401, NCT02523014: Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients with Progressive Meningiomas

Recruiting
2
124
US
Vismodegib, GDC-0449, FAK Inhibitor GSK2256098, Capivasertib, AZD5363, Abemaciclib
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), GlaxoSmithKline, Genentech, Inc., Brain Science Foundation
Intracranial Meningioma, Recurrent Meningioma, NF2 Gene Mutation
01/26
01/28
NCT03994796: Genetic Testing in Guiding Treatment for Patients with Brain Metastases

Recruiting
2
186
US
Abemaciclib, PI3K Inhibitor paxalisib, Entrectinib, Adagrasib, MRTX849
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Mirati Therapeutics Inc., Genentech, Inc., Eli Lilly and Company, Kazia Therapeutics Limited
CDK Gene Mutation, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, NTRK Family Gene Mutation, PI3K Gene Mutation, ROS1 Gene Mutation, KRAS G12C Mutation
10/26
06/28
NCT03173950: Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers

Active, not recruiting
2
108
US
Nivolumab
National Cancer Institute (NCI)
Medulloblastoma, Ependymoma, Pineal Region Tumors, Choroid Plexus Tumors, Atypical/Malignant Meningioma
07/25
07/26
SC9/ABX, NCT04528680: Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Glioblastoma

Recruiting
1/2
57
US
Sonication for opening of blood-brain barrier, SonoCloud-9 device, SC-9, Chemotherapy, albumin-bound paclitaxel, Abraxane®, ABX, Chemotherapy, carboplatin, Paraplatin
Northwestern University, CarThera, Bristol-Myers Squibb, Lantheus Medical Imaging
Glioblastoma, Gliosarcoma, GBM, Glioblastoma Multiforme, Glioblastoma, IDH-wildtype, Recurrent Glioblastoma
09/24
09/25
NCT04588545: Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease

Recruiting
1/2
39
US
Radiation Therapy, Pertuzumab, Trastuzumab
H. Lee Moffitt Cancer Center and Research Institute, Genentech, Inc.
HER2-positive Breast Cancer, Leptomeningeal Metastasis, Leptomeningeal Disease
07/25
07/25
NCT05236036: Mycophenolate Mofetil in Combination With Standard of Care for the Treatment of Glioblastoma

Recruiting
1
60
US
Mycophenolate Mofetil, CellCept, MMF, Quality-of-Life Assessment, Quality of Life Assessment, Radiation Therapy, Cancer Radiotherapy, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Temozolomide, CCRG-81045, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temodal, Temodar, Temomedac, TMZ
Northwestern University, National Cancer Institute (NCI)
Astrocytoma, Glioblastoma, Glioblastoma, IDH-Wildtype, MGMT-Unmethylated Glioblastoma, Recurrent Glioblastoma
01/25
01/27
ReSPECT-LM, NCT05034497: Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases

Recruiting
1
18
US
186RNL, Rhenium-186 NanoLiposome
Plus Therapeutics
Leptomeningeal Metastasis
12/25
06/26
FORESEE, NCT05414123: A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide

Terminated
N/A
40
US
CNSide
Biocept, Inc., ICON plc
Leptomeningeal Metastasis, Leptomeningeal Disease, Leptomeningeal Neoplasms, Breast Cancer, Non-Small Cell Lung Cancer
10/23
10/23
Tate, Matthew
ReSPECT-LM, NCT05034497: Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases

Recruiting
1
18
US
186RNL, Rhenium-186 NanoLiposome
Plus Therapeutics
Leptomeningeal Metastasis
12/25
06/26
FORESEE, NCT05414123: A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide

Terminated
N/A
40
US
CNSide
Biocept, Inc., ICON plc
Leptomeningeal Metastasis, Leptomeningeal Disease, Leptomeningeal Neoplasms, Breast Cancer, Non-Small Cell Lung Cancer
10/23
10/23
Dixit, Karan
ACTION, NCT05580562: ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the Study)

Calendar Jan 2026 - Dec 2026: Final data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma
Calendar Jan 2025 - Mar 2025: Interim data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma
Recruiting
3
450
Europe, Canada, Japan, US, RoW
Dordaviprone (ONC201), Dordaviprone (ONC201) + Placebo, Placebo
Chimerix
H3 K27M, Glioma
08/26
08/26
NCT02847559: Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma

Recruiting
2
27
US
Bevacizumab, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF rhuMAb, Avastin, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, Electric Field Therapy, NovoTTF-200A Device, NovoTTF-200A, NovoTTF-200A System, NovoTTFields, NovoTumor Treatment Fields, Optune, Optune Device, Quality-of-Life Assessment, Quality of Life Assessment
Northwestern University, NovoCure Ltd., National Cancer Institute (NCI)
Anaplastic (Malignant) Meningioma, Atypical Meningioma, Grade II Meningioma, Grade III Meningioma, Recurrent Meningioma, Supratentorial Meningioma
09/26
12/26
SC9/ABX, NCT04528680: Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Glioblastoma

Recruiting
1/2
57
US
Sonication for opening of blood-brain barrier, SonoCloud-9 device, SC-9, Chemotherapy, albumin-bound paclitaxel, Abraxane®, ABX, Chemotherapy, carboplatin, Paraplatin
Northwestern University, CarThera, Bristol-Myers Squibb, Lantheus Medical Imaging
Glioblastoma, Gliosarcoma, GBM, Glioblastoma Multiforme, Glioblastoma, IDH-wildtype, Recurrent Glioblastoma
09/24
09/25
NCT02530502: Radiation Therapy With Temozolomide and Pembrolizumab in Treating Patients With Newly Diagnosed Glioblastoma

Terminated
1
4
US
Laboratory Biomarker Analysis, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Radiation Therapy, Cancer Radiotherapy, Irradiate, Irradiated, Irradiation, RADIATION, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Temozolomide, CCRG-81045, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temodal, Temodar
Northwestern University, Merck Sharp & Dohme LLC, National Cancer Institute (NCI)
Adult Glioblastoma
05/16
02/20
NCT06410248: Triapine in Combination with Temozolomide for the Treatment of Patients with Recurrent Glioblastoma

Recruiting
1
30
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Questionnaire Administration, Resection, Surgical Resection, Temozolomide, CCRG-81045, Gliotem, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temizole, Temodal, Temodar, Temomedac, TMZ, Triapine, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, 3-AP, 3-Apct, OCX-0191, OCX-191, OCX191, PAN-811
Northwestern University, National Cancer Institute (NCI), BrainUp Inc
Recurrent Glioblastoma, IDH-Wildtype, Recurrent WHO Grade 2 Glioma, Recurrent WHO Grade 3 Glioma, Recurrent WHO Grade 4 Glioma
05/29
05/30
ReSPECT-LM, NCT05034497: Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases

Recruiting
1
18
US
186RNL, Rhenium-186 NanoLiposome
Plus Therapeutics
Leptomeningeal Metastasis
12/25
06/26
Thomas, Tiffany
ChonDRAgon, NCT04950075: Study of INBRX-109 in Conventional Chondrosarcoma

Recruiting
2
201
Europe, US, RoW
INBRX-109, Placebo
Inhibrx Biosciences, Inc
Conventional Chondrosarcoma
09/25
12/26
ENGOT-ov60, NCT04625270 / 2020-004264-26: A Study of Avutometinib (VS-6766) V. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer with and Without a KRAS Mutation

Active, not recruiting
2
225
Europe, Canada, US
avutometinib (VS-6766), avutometinib (VS-6766) and defactinib, avutometinib (VS-6766) and VS-6063
Verastem, Inc., European Network of Gynaecological Oncological Trial Groups (ENGOT), GOG Foundation
Low Grade Ovarian Serous Adenocarcinoma, Ovarian Cancer
11/24
12/26
KURRENT-HN, NCT04997902: Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

Recruiting
1/2
40
US
Tipifarnib, Alpelisib, BYL719
Kura Oncology, Inc.
HNSCC
07/25
07/25
Raslan, Omar
NCT05326464: Tofacitinib in Recurrent GBM Patients

Recruiting
3
20
US
Tofacitinib 10mg
University of Texas Southwestern Medical Center, Pfizer
Glioblastoma
06/25
06/26
ReSPECT-GBM, NCT01906385: Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)

Recruiting
1/2
55
US
Rhenium Liposome Treatment, Rhenium-186 NanoLiposome
Plus Therapeutics, National Cancer Institute (NCI)
Glioma
01/25
01/25
ReSPECT-LM, NCT05034497: Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases

Recruiting
1
18
US
186RNL, Rhenium-186 NanoLiposome
Plus Therapeutics
Leptomeningeal Metastasis
12/25
06/26
gonzalez, nancy navarro
NCT04315792: Evaluate Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients

Completed
3
124
US
Endoxifen, Placebo oral tablet
Jina Pharmaceuticals Inc., Novum Pharmaceutical Research Services, Lambda Therapeutic Research Ltd.
Bipolar I Disorder
01/21
08/21
MBD, NCT03395392: NRX-101 for Bipolar Depression With Subacute Suicidal Ideation

Completed
2/3
74
US
NRX-101, Lurasidone HCl, Latuda
NeuroRx, Inc., Prevail Infoworks, Inc
Bipolar Depression, Suicidal Ideation and Behavior
02/24
03/24
ReSPECT-LM, NCT05034497: Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases

Recruiting
1
18
US
186RNL, Rhenium-186 NanoLiposome
Plus Therapeutics
Leptomeningeal Metastasis
12/25
06/26
Youssef, Michael
NCT05326464: Tofacitinib in Recurrent GBM Patients

Recruiting
3
20
US
Tofacitinib 10mg
University of Texas Southwestern Medical Center, Pfizer
Glioblastoma
06/25
06/26
NCT00887146 / 2008-007295-14: Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma

Active, not recruiting
3
305
Europe, Canada, US
concomitant temozolomide (TMZ), radiotherapy, procarbazine, adjuvant temozolomide (TMZ), CCNU, vincristine
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), European Organisation for Research and Treatment Center (EORTC), Canadian Cancer Trials Group
Brain and Central Nervous System Tumors
10/25
10/25
NRG-BN011, NCT05095376: Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine®) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma

Recruiting
3
306
Canada, US
Lomustine, 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea, 1-Nitrosourea, 1-(2-chloroethyl)-3-cyclohexyl-, Belustin, Belustine, CCNU, Cecenu, CeeNU, Chloroethylcyclohexylnitrosourea, Citostal, Gleostine, Lomeblastin, Lomustinum, Lucostin, Lucostine, N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea, Prava, RB-1509, WR-139017, Photon Beam Radiation Therapy, Photon EBRT, Photon External Beam Radiotherapy, Radiation, Photon Beam, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Temozolomide, CCRG-81045, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temodal, Temodar, Temomedac, TMZ
NRG Oncology, National Cancer Institute (NCI)
Glioblastoma, Gliosarcoma
08/26
08/31
GBM AGILE, NCT03970447 / 2020-002250-24: A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Calendar Jan 2030 - Dec 2030: Market entry for glioblastoma
Oct 2023 - Dec 2023: Top-line data from GBM AGILE trial for glioblastoma
Recruiting
2/3
1030
Europe, Canada, US, RoW
Temozolomide, Temodar, Temodal, Temcad, Lomustine, CCNU, CeeNU, Gleostine, Regorafenib, Stivarga, BAY 73-4506, Radiation, Paxalisib, GDC-0084, VAL-083, Dianhydrogalactitol, VT1021, Troriluzole, BHV-4157, ADI-PEG 20, Pegargiminase
Global Coalition for Adaptive Research, Bayer, Kazia Therapeutics Limited, Kintara Therapeutics, Inc., Biohaven Pharmaceuticals, Inc., Vigeo Therapeutics, Inc., Polaris Group
Glioblastoma
06/26
06/28
NCT04145115: A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden

Suspended
2
37
US
Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS 734016, BMS-734016, BMS734016, Ipilimumab Biosimilar CS1002, MDX 010, MDX-010, MDX-CTLA4, MDX010, Yervoy, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo
National Cancer Institute (NCI)
Astrocytoma, IDH-Mutant, Grade 4, Diffuse Glioma, Glioblastoma, IDH-Wildtype, Secondary Glioblastoma
05/25
05/25
NCT03994796: Genetic Testing in Guiding Treatment for Patients with Brain Metastases

Recruiting
2
186
US
Abemaciclib, PI3K Inhibitor paxalisib, Entrectinib, Adagrasib, MRTX849
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Mirati Therapeutics Inc., Genentech, Inc., Eli Lilly and Company, Kazia Therapeutics Limited
CDK Gene Mutation, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, NTRK Family Gene Mutation, PI3K Gene Mutation, ROS1 Gene Mutation, KRAS G12C Mutation
10/26
06/28
ReSPECT-LM, NCT05034497: Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases

Recruiting
1
18
US
186RNL, Rhenium-186 NanoLiposome
Plus Therapeutics
Leptomeningeal Metastasis
12/25
06/26
FORESEE, NCT05414123: A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide

Terminated
N/A
40
US
CNSide
Biocept, Inc., ICON plc
Leptomeningeal Metastasis, Leptomeningeal Disease, Leptomeningeal Neoplasms, Breast Cancer, Non-Small Cell Lung Cancer
10/23
10/23

Download Options